Suppression of GH and IGF-I can be achieved by treatment with somatostatin analogues, which provide safe and effective management of acromegaly.5–7 The somatostatin analogue lanreotide is available as a long-acting aqueous gel formulation, lanreotide Autogel (Beaufour Ipsen Pharma, Paris, France), which is administered subcutaneously every 28 days from a ready-to-use prefilled syringe. The gene discussed is IGF1; the disease is acromegaly.